Medicine for treating bedsore and application thereof

Abstract

The invention discloses a medicine for treating bedsore and application thereof.The medicine is prepared from parthenocissus tricuspidata, clove, radix aucklandiae and borneol, the parthenocissus tricuspidata serves as a monarch drug and has the effects of promoting blood circulation, removing toxins, removing blood stasis, dredging collaterals, improving local blood circulation of bedsore, promoting inflammation fading, dissolving sore and ulcer toxins and repairing damaged tissue; the clove is used as a ministerial drug to expel pus and engender tissue, inhibit wound infection and promote healing of ulcerated wounds; the radix aucklandiae is used as an adjuvant drug for promoting qi circulation, promoting blood circulation and promoting qi hyperactivity and blood circulation, and the radix aucklandiae is used as a monarch drug for removing stasis and dredging collaterals to nourish tendons and meat; borneol is used as an assistant drug, is used for resisting bacteria, relieving pain and promoting healing of non-healing after bedsore ulceration, and also can be used as a meridian guiding drug to enhance the seepage force of the drug so as to promote external transdermal absorption of the drug. Through simple composition and reasonable compatibility of the medicines, local qi and blood stasis of bedsores can be improved and wound healing can be promoted through the multi-target effect by activating blood and detoxifying, expelling pus and promoting tissue regeneration and inhibiting bacteria to control infection, so that the bedsores can be effectively treated.

Description

Technical Field

[0001] The invention relates to the technical field of traditional Chinese medicines, and in particular to a medicine for treating bedsores and application thereof. Background Art

[0002] Bedsores, also known as "pressure sores", "bed sores" and "pressure ulcers", are localized injuries to the skin, muscles or subcutaneous tissue caused by pressure, shear force or friction, and often occur on bony prominences; this disease is similar to the TCM name "bed sores". It is common in patients who have been bedridden or sitting for a long time. Due to long-term pressure and friction, local skin and flesh are ischemic, hypoxic and necrotic. Bedsores not only affect the patient's quality of life and health, but also bring huge burdens to the family and society.

[0003] According to the latest clinical classification of the National Bedsore Advisory Group of the United States in 2007, bedsores can be divided into the following four stages: Stage I bedsores: Congestion and ruddy stage - "redness, swelling, heat, pain or numbness, which lasts for 30 minutes", the skin at the bony protuberance is intact with localized erythema that does not fade when pressed. Stage II bedsores: Inflammatory infiltration stage - "purple, nodules, pain, blisters", partial loss of dermis, manifested as a shallow open ulcer, no tissue necrosis, or may also manifest as a complete or ruptured serum blister. Stage III: Shallow ulcer stage of bedsores - epidermis is damaged, ulcers are formed, the whole layer of skin tissue is lost, subcutaneous fat is exposed, but bones, tendons and muscles are not exposed, and there is necrotic tissue in the wound. Stage IV: Necrotic ulcer stage of bedsores - necrosis of subdermal tissue, infection spreads to the muscle layer and bone surface, often with full-thickness tissue loss, accompanied by exposed bones, tendons or muscles, and often with undercover tunnels.

[0004] Western medicine mostly uses antibiotics, which are prone to bacterial resistance and poor in effect. In addition, some patients' bedsores may need to undergo multiple debridements when treated with Western medicine. If the operation is not done properly, it is easy to cause the bedsore wound to continue to expand as the debridement proceeds. In recent years, research on TCM treatment of bedsores has also been developing, but some TCM prescriptions have many types of raw materials and are relatively complex, resulting in high costs and unsatisfactory efficacy. Summary of the invention

[0005] Therefore, based on the above background, the present invention provides a drug with a simple composition that can effectively improve and treat bedsores.

[0006] The technical solution provided by the present invention is:

[0007] A medicine for treating bedsores, which is made from the following raw materials in parts by weight:

[0008] 10-30 parts of Parthenocissus tricuspidata, 30-60 parts of cloves, 5-15 parts of costusroot, and 5-15 parts of borneol.

[0009] Furthermore, it is made from the following raw materials in parts by weight:

[0010] 20 parts of Parthenocissus tricuspidata, 50 parts of Syzygium aromaticum, 10 parts of Aucklandia lappa, and 10 parts of Borneol.

[0011] Furthermore, it is made from the following raw materials in parts by weight:

[0012] 30 parts of Parthenocissus tricuspidata, 50 parts of Syzygium aromaticum, 12 parts of Aucklandia lappa, and 12 parts of Borneol.

[0013] Based on the same inventive concept, the present invention applies the above-mentioned drug to the preparation of an external preparation for treating bedsore.

[0014] Furthermore, the external preparation is a powder or a plaster.

[0015] Based on the same inventive concept, the present invention applies the above-mentioned drug to the preparation of an external preparation for treating burns and scalds.

[0016] Furthermore, the external preparation is a powder or a plaster.

[0017] The pharmacology of the present invention is as follows:

[0018] Parthenocissus tricuspidata activates blood circulation to detoxify and disperse stasis and dredge collaterals; Syzygium aromaticum warms the middle-jiao to dispel cold, drains pus, reduces swelling and has anti-inflammatory and antibacterial effects; Aucklandia lappa promotes qi flow to relieve pain and promotes blood circulation to remove stasis; Borneol clears heat and relieves pain, inhibits bacteria and relieves itching.

[0019] Traditional Chinese medicine believes that the pathogenesis of bedsore is mainly local qi stagnation and blood stasis. If the stasis persists for a long time, the flesh will fester. Therefore, the present invention rationally combines and uses drugs according to the pathogenesis. Using Parthenocissus tricuspidata as the monarch drug to activate blood circulation to detoxify, remove stasis and dredge collaterals, improve local blood circulation of bedsore, promote the subsidence of inflammation, resolve sore toxins, and repair damaged tissues; using Syzygium aromaticum as the minister drug to drain pus and promote granulation, inhibit wound surface infection, and promote the healing of festering wounds; using Aucklandia lappa as the assistant drug to promote qi flow and promote blood circulation. When qi is strong, blood circulation is promoted, strengthening the effect of the monarch drug in removing stasis and dredging collaterals, and the muscles and tendons can be nourished; using Borneol as the guiding drug, with its antibacterial and pain-relieving effects, helping to promote the healing of non-healing bedsore after ulceration, and also serving as a guiding drug to enhance the penetration of drugs to assist the transdermal absorption of external drugs. And the formula of the present invention has a balanced nature and flavor, and the cold nature of Borneol balances the warm nature of Syzygium aromaticum and Aucklandia lappa. Through the simple composition and reasonable compatibility of drugs, the present invention can improve local qi and blood stasis of bedsore, promote wound surface healing, and effectively treat bedsore through multi-target effects by activating blood circulation to detoxify, draining pus and promoting granulation, and inhibiting bacteria to control infection.

[0020] Moreover, the present invention can activate blood circulation to detoxify, drain pus and promote granulation, and can promote the healing effect of sore wounds, and it also has a certain therapeutic effect on burns and scalds. Detailed implementation mode

[0021] To make the objectives, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of them. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts belong to the scope of protection of the present invention.

[0022] Example 1: A drug for treating bedsore, which is made from the following raw materials in parts by weight:

[0023] 20 parts of Parthenocissus tricuspidata, 50 parts of Syzygium aromaticum, 10 parts of Aucklandia lappa, and 10 parts of Borneol.

[0024] Example 2: A drug for treating bedsore, which is made from the following raw materials in parts by weight:

[0025] 30 parts of Parthenocissus tricuspidata, 50 parts of Syzygium aromaticum, 12 parts of Aucklandia lappa, and 12 parts of Borneol.

[0026] The Parthenocissus tricuspidata, Syzygium aromaticum, and Aucklandia lappa in Example 1 and Example 2 are all processed conventionally.

[0027] For example, Parthenocissus tricuspidata is processed with wine: Sprinkle and mix evenly with yellow rice wine, moisten it by covering, and then stir-fry slightly to enhance the power of promoting blood circulation and dredging collaterals.

[0028] Syzygium aromaticum is stir-fried without oil:

[0029] Place the dried and cleaned Syzygium aromaticum in a medicine frying pan preheated to 80°C;

[0030] Stir-fry gently over low heat until the surface color slightly deepens (slightly yellowish brown) and emits a strong aroma;

[0031] Quickly take it out and spread it out to cool, avoiding overheating.

[0032] Aucklandia lappa is stir-fried:

[0033] Stir-fry the dried Aucklandia lappa slices or pieces in a frying pan over low heat until the aroma is strong and the color slightly darkens, then take it out and spread it out to cool.

[0034] The drugs in Example 1 and Example 2 are prepared into powders:

[0035] After taking the raw materials according to the amount, crush them respectively, pass through an 80-100 mesh sieve, and then mix evenly.

[0036] The drugs in Example 1 and Example 2 are made into ointments:

[0037] After taking the raw materials according to the amount, crush them respectively, pass through an 80-100 mesh sieve, add sesame oil or sesame seed oil, and it will be in a paste state.

[0038] Comparative Example 1: A drug for treating bedsore, which is made from the following raw materials in parts by weight:

[0039] 20 parts of Cortex Moutan, 50 parts of Flos Caryophylli, 10 parts of Radix Aucklandiae, 10 parts of Borneol.

[0040] In this comparative example compared with Example 1, Cortex Moutan, which also has the effects of promoting blood circulation to remove stasis and detoxification, activating blood circulation and dredging collaterals, was used to replace Parthenocissus tricuspidata.

[0041] Comparative Example 2: A drug for treating bedsore, which is made from the following raw materials in parts by weight:

[0042] 20 parts of Parthenocissus tricuspidata, 50 parts of Radix Angelicae Dahuricae, 10 parts of Radix Aucklandiae, 10 parts of Borneol.

[0043] The groups of Comparative Example 1 and Comparative Example 2 were prepared into ointments in the same way as Example 1.

[0044] In this comparative example compared with Example 1, Radix Angelicae Dahuricae, which also has the effect of detumescence and discharging pus, was used to replace Flos Caryophylli.

[0045] Pharmacodynamic verification:

[0046] 20 third-stage pressure sore models (constructed by metal implantation method, purchased from Wuhan Besai Model Biotechnology Co., Ltd.) were bought and randomly divided into 4 groups, namely the control group, the example group, the Comparative Example 1 group and the Comparative Example 2 group. In the example group, the ointment prepared in Example 1 was evenly applied to the wound surface of mice every day. In the Comparative Example 1 group, the ointment prepared in Comparative Example 1 was evenly applied to the wound surface of mice every day. In the Comparative Example 2 group, the ointment prepared in Comparative Example 2 was evenly applied to the wound surface of mice every day. In the control group, normal saline was applied to the wound surface of mice every day. Each group was caged separately, and the mice were allowed to eat and drink freely.

[0047] On the 1st day, 7th day and 14th day respectively, the wound surface areas of mice in each group were measured by the grid method, and the average values of each group of mice were taken. The results are shown in Table 1 below.

[0048] Table 1: Skin wound surface areas of mice in each group (mm 2 )

[0049] Group Day 1 Day 7 Day 14 Control Group 223.5 147.4 102.1 Example Group 222.9 86.3 19.7 Comparative Example 1 Group 223.1 115.8 77.6 Comparative Example 2 Group 223.7 104.2 46.9

[0050] As can be seen from the above table, after 14 days, compared with the control group, the wound healing conditions of the example group, the Comparative Example 1 group and the Comparative Example 2 group were significantly better. And the wound healing condition of the example group was better than that of the Comparative Example 1 group and the Comparative Example 2 group. That is, the wound recovery condition of the mice in the example group was better than that in the Example 1 group and the Example 2 group. Then, after replacing Parthenocissus tricuspidata with Cortex Moutan with the same pharmacodynamic effect and replacing Flos Caryophylli with Radix Angelicae Dahuricae, the pharmacodynamic effect of the whole formula decreased. Obviously, the replacement and adjustment of the formula in Comparative Example 1 and Comparative Example 2 compared with Example 1 led to the destruction of the monarch-minister-assistant-guide balance relationship of the formula, resulting in a significant reduction in the overall wound healing effect.

[0051] Typical cases:

[0052] The drug of the present invention has been applied to the treatment of bedsore in hundreds of cases, and all patients have reported significant treatment effects.

[0053] The following lists some typical cases of using the present invention for the treatment of bedsore.

[0054] Case 1: Li Mou, female, 51 years old. After having a stroke in 2023 and lying in bed for 3 months, due to improper nursing, bedsore occurred. The skin at the sacral tail showed redness, swelling and ulceration, and there was pus oozing out from time to time. She used the drug of Example 1 for treatment. On the first day, she rinsed with clean water, removed the rotten substances at the affected area, and applied the powder externally to the affected area. The powder could absorb the pus. On the second day, the paste agent was evenly applied to the affected area. After the second day of treatment, the pus oozing was significantly reduced. Then, the paste agent was applied to the affected area every day. On the third day of medication, the wound surface began to scab. After continuing the treatment for 5 days, the affected area began to desquamate. After continuing to use the drug for treatment for 3 days, after complete desquamation, no scar was produced.

[0055] Case 2: Gao Mou, male, 65 years old. After being injured in 2024 and lying in bed for half a year, the skin on the back showed large-area redness and swelling, and there were blisters of different sizes and some ulcerated areas in some parts, and there was fluid oozing from time to time. He used the drug of Example 1 of the present invention for treatment. On the first day, he rinsed with clean water, removed the rotten substances at the affected area, and applied the powder externally to the affected area. The powder could absorb the pus. On the second day, the paste agent was evenly applied to the affected area. After the fourth day of treatment, the skin redness and pus oozing were significantly reduced. After the number and size of the local blisters were reduced, the paste agent was applied to the affected area every day. On the seventh day of medication, the wound surface began to scab. After continuing the treatment for 7 days, the affected area began to desquamate. Continue to use the drug until complete desquamation.

[0056] The drug of the present invention is also used for the treatment of burn and scald patients. The following are some cases of the treatment of burn and scald patients.

[0057] Case 1: Yuan Mou, male, 6 years old. Due to being naughty in the kitchen, his arm touched the boiling kettle. Although he immediately rinsed with cold water, the skin on his forearm still blistered and was significantly red and swollen, and ulceration occurred on the second day. He immediately applied the powder drug of Example 1 of the present invention externally to the affected area. On the second day of treatment, the paste agent was evenly applied to the affected area. After the third day of treatment, the blisters and redness and swelling at the ulcerated area subsided significantly. After the fifth day of treatment, the affected area began to scab.

[0058] The above describes the present invention and its implementation manners. Such description is not restrictive. What is shown in the embodiments is only one of the implementation manners of the present invention, and the actual structure is not limited thereto. In general, if those of ordinary skill in the art are inspired by it and, without departing from the gist of the present invention, creatively design structural manners and embodiments similar to the technical solution, they shall fall within the protection scope of the present invention.

Claims

1. A drug for treating bedsores, characterized in that: It is made of the following raw materials in parts by weight: 10-30 parts of Parthenocissus tricuspidata, 30-60 parts of cloves, 5-15 parts of costusroot, and 5-15 parts of borneol.

2. A drug for treating bedsores according to claim 1, characterized in that: It is made of the following raw materials in parts by weight: 20 parts of Parthenocissus tricuspidata, 50 parts of cloves, 10 parts of costusroots, and 10 parts of borneol.

3. A drug for treating bedsores according to claim 1 or 2, characterized in that: It is made of the following raw materials in parts by weight: 30 parts of Parthenocissus tricuspidata, 50 parts of cloves, 12 parts of costusroots, and 12 parts of borneol.

4. Use of the drug according to any one of claims 1 to 3 in the preparation of an external preparation for treating bedsores.

5. The use according to claim 4, characterized in that: The external preparation is a powder or a plaster.

6. Use of the drug according to any one of claims 1 to 3 in the preparation of an external preparation for treating burns and scalds.

7. The use according to claim 6, characterized in that: The external preparation is a powder or a plaster.